2,435.00
-21.00
(-0.86%)
At close: January 30 at 5:24:48 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
158,380.00
142,519.00
129,339.00
103,642.00
133,246.00
Cost of Revenue
91,032.00
87,029.00
82,636.00
73,314.00
85,694.00
Gross Profit
67,348.00
55,490.00
46,703.00
30,328.00
47,552.00
Operating Expense
49,599.00
45,426.00
42,171.00
31,024.00
28,315.00
Operating Income
17,749.00
10,064.00
4,532.00
-696.00
19,237.00
Net Non Operating Interest Income Expense
1,504.00
-710.00
-823.00
12.00
761.00
Other Income Expense
-3,354.00
-925.00
-5,968.00
-1,201.00
-1,433.00
Pretax Income
15,899.00
8,429.00
-2,259.00
-1,885.00
18,565.00
Tax Provision
187.00
145.00
62.00
345.00
1,425.00
Net Income Common Stockholders
15,712.00
8,284.00
-2,321.00
-2,230.00
17,140.00
Diluted NI Available to Com Stockholders
15,712.00
8,284.00
-2,321.00
-2,230.00
17,140.00
Basic EPS
0.29
0.17
-0.05
-0.05
0.39
Diluted EPS
0.27
0.15
-0.05
-0.05
0.38
Basic Average Shares
56,321.46
48,830.48
46,420.00
44,600.00
43,948.72
Diluted Average Shares
57,742.18
53,675.51
46,420.00
44,600.00
45,105.26
Total Operating Income as Reported
17,749.00
10,064.00
4,532.00
-696.00
19,237.00
Total Expenses
140,631.00
132,455.00
124,807.00
104,338.00
114,009.00
Net Income from Continuing & Discontinued Operation
15,712.00
8,284.00
-2,321.00
-2,230.00
17,140.00
Normalized Income
18,058.08
8,229.95
-2,550.46
-2,070.61
18,462.66
Interest Income
1,930.00
588.00
91.00
295.00
1,027.00
Interest Expense
426.00
1,298.00
914.00
283.00
266.00
Net Interest Income
1,504.00
-710.00
-823.00
12.00
761.00
EBIT
16,325.00
9,727.00
-1,345.00
-1,602.00
18,831.00
EBITDA
29,241.00
22,441.00
10,810.00
4,007.00
23,728.00
Reconciled Cost of Revenue
91,032.00
77,440.00
73,510.00
69,068.00
81,723.00
Reconciled Depreciation
12,916.00
12,714.00
12,155.00
5,609.00
4,897.00
Net Income from Continuing Operation Net Minority Interest
15,712.00
8,284.00
-2,321.00
-2,230.00
17,140.00
Total Unusual Items Excluding Goodwill
-2,374.00
55.00
298.00
-207.00
-1,433.00
Total Unusual Items
-2,374.00
55.00
298.00
-207.00
-1,433.00
Normalized EBITDA
31,615.00
22,386.00
10,512.00
4,214.00
25,161.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-27.92
0.95
68.54
-47.61
-110.34
12/31/2020 - 8/31/2005
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
REKA.TA Rekah Pharmaceutical Industry Ltd.
1,344.00
-2.68%
SEMG.TA Seach Medical Group Ltd
300.70
+0.77%
INCR.TA InterCure Ltd.
585.00
-3.23%
MOB.ST Moberg Pharma AB (publ)
9.51
+1.71%
INCR InterCure Ltd.
1.6699
-0.60%
TEVA.TA Teva Pharmaceutical Industries Limited
6,400.00
-5.67%
RDHL RedHill Biopharma Ltd.
5.93
-2.15%
PRGO Perrigo Company plc
24.93
+1.05%
TAK Takeda Pharmaceutical Company Limited
13.70
+2.93%
TEVA Teva Pharmaceutical Industries Limited
17.84
-3.78%